Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery

Marie Stark, R. Holland Cheng

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalPharmaceutical patent analyst
Volume5
Issue number5
DOIs
StatePublished - Sep 1 2016

Keywords

  • cancer targeting
  • nanotheranostics
  • viral capsid

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery'. Together they form a unique fingerprint.

  • Cite this